Effect of adjunctive roxithromycin therapy on interleukin-1β, transforming growth factor-β1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth

Journal of Periodontal Research

Volumn 49, Issue 4, 2014, Pages 448-457

  Gong, Y ^a   Lu, J ^b   Ding, X ^a   Yu, Y ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cyclosporine A; Gingival overgrowth; Interleukin 1 ; Periodontal therapy; Roxithromycin; Vascular endothelial growth factor

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOSPORIN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; PLACEBO; ROXITHROMYCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; CHEMICALLY INDUCED; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; FOLLOW UP; GINGIVAL OVERGROWTH; GINGIVITIS; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIODONTAL POCKET; PERIODONTICS; PREVENTIVE DENTISTRY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TOOTH PLAQUE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; CYCLOSPORINE; DENTAL PLAQUE INDEX; DENTAL SCALING; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GINGIVAL CREVICULAR FLUID; GINGIVAL OVERGROWTH; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PERIODONTAL INDEX; PERIODONTAL POCKET; PLACEBOS; ROOT PLANING; ROXITHROMYCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904068734     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12123     Document Type: Article

References (52)

1. Rateitschak-Plüss EM, Hefti A, Lörtscher R, Thiel G. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983;10:237-246.
2. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-223.
3. Trackman PC, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med 2004;15:165-175.
4. Mavrogiannis M, Ellis JS, Thomason JM, Seymour RA. The management of drug-induced gingival overgrowth. J Clin Periodontol 2006;33:434-439.
5. Kantarci A, Cebeci I, Tuncer O, Carin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. J Periodontol 1999;70:587-593.
6. Pernu HE, Pernu LM, Knuuttila ML. Effect of periodontal treatment on gingival overgrowth among cyclosporine A-treated renal transplant recipients. J Periodontol 1993;64:1098-1110.
7. Somacarrera ML, Lucas M, Scully C, Barrios C. Effectiveness of periodontal treatments on cyclosporine-induced gingival overgrowth in transplant patients. Br Dent J 2005;183:89-94.
8. Vardar S, Baylas H, Zihnioǧlu F, Buduneli N, Emingil G, Atilla G. Gingival tissue proteoglycan and chondroitin-4-sulphate levels in cyclosporin A-induced gingival overgrowth and the effects of initial periodontal treatment. J Clin Periodontol 2005;32:634-639.
9. Aimetti M, Romano F, Debernardi C. Effectiveness of periodontal therapy on the severity of cyclosporin A-induced gingival overgrowth. J Clin Periodontol 2005;32:846-850.
10. Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation 1998;65:1611-1615.
11. Gómez E, Sánchez-Nuñez M, Sánchez JE, Portal C, Alvarez-Grande J. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant 1997;12:2694-2697.
12. Ramalho VL, Ramalho HJ, Cipullo JP, Azoubel R, Burdmann EA. Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia. Ren Fail 2007;29:265-270.
13. Chand DH, Quattrocchi J, Poe SA, Terezhalmy GT, Strife CF, Cunningham RJ. Trial of metronidazole vs. azithromycin for treatment of cyclosporine-induced gingival overgrowth. Pediatr Transplant 2004;8:60-64.
14. Sánchez-Nuñez ML, Gómez E, Sánchez JE et al. Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia. Nephrol Dial Transplant 1997;12:2040-2041.
15. Mesa FL, Osuna A, Aneiros J et al. Antibiotic treatment of incipient drug-induced gingival overgrowth in adult renal transplant patients. J Periodontal Res 2003;38:141-146.
16. Hirsch R, Deng H, Laohachai MN. Azithromycin in periodontal treatment: more than an antibiotic. J Periodontal Res 2012;47:137-148.
17. Kim JY, Park SH, Cho KS et al. Mechanism of azithromycin treatment on gingival overgrowth. J Dent Res 2008;87: 1075-1079.
18. Paik JW, Kim CS, Cho KS, Chai JK, Kim CK, Choi SH. Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. J Periodontol 2004;75:380-387.
19. Condé SA, Aarestrup FM, Vieira BJ, Bastos MG. Roxithromycin reduces cyclosporine-induced gingival hyperplasia in renal transplant patients. Transplant Proc 2008;40:1435-1438.
20. Gao X, Ray R, Xiao Y, Barker PE, Ray P. Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol 2007;8:17.
21. Yamabe H, Shimada M, Kaizuka M et al. Roxithromycin inhibits transforming growth factor-beta production by cultured human mesangial cells. Nephrology (Carlton) 2006;11:524-530.
22. Condé SA, Bastos MG, Vieira BJ, Aarestrup FM. Down-regulation of transforming growth factor beta-2 expression is associated with the reduction of cyclosporin induced gingival overgrowth in rats treated with roxithromycin: an experimental study. BMC Oral Health 2009;9:33.
23. Oyama T, Sakuta T, Matsushita K, Maruyama I, Nagaoka S, Torii M. Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. J Periodontol 2000;71:1546-15453.
24. Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
25. Saxer UP, Mühlemann HR. Motivation and education. SSO Schweiz Monatsschr Zahnheilkd 1975;85:905-919.
26. Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985;12:413-419.
27. Guggenheimer J, Mayher D, Eghtesad B. A survey of dental care protocols among US organ transplant centers. Clin Transplant 2005;19:15-18.
28. Kuru L, Griffiths GS, Petrie A, Olsen I. Changes in transforming growth factor-beta1 in gingival crevicular fluid following periodontal surgery. J Clin Periodontol 2004;31:527-533.
29. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000;71:1535-1545.
30. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292: 156-163.
31. Matarese G, Isola G, Anastasi GP et al. Immunohistochemical analysis of TGF-β1 and VEGF in gingival and periodontal tissues: a role of these biomarkers in the pathogenesis of scleroderma and periodontal disease. Int J Mol Med 2012;30:502-508.
32. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-4345.
33. Linden GJ, Haworth SE, Maxwell AP et al. The influence of transforming growth factor-beta1 gene polymorphisms on the severity of gingival overgrowth associated with concomitant use of cyclosporin A and a calcium channel blocker. J Periodontol 2001;72:808-814.
34. Wright HJ, Chapple IL, Blair F, Matthews JB. Crevicular fluid levels of TGFbeta1 in drug-induced gingival overgrowth. Arch Oral Biol 2004;49:421-425.
35. Radwan-Oczko M, Boratyńska M, Zietek M, Zołedziewska M, Jonkisz A. The relationship of transforming growth factor-beta1 gene polymorphism, its plasma level, and gingival overgrowth in renal transplant recipients receiving different immunosuppressive regimens. J Periodontol 2006;77:865-873.
36. Chen YT, Tu HP, Chin YT et al. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor gene and protein expression in cyclosporin-induced overgrown edentulous gingiva in rats. J Periodontol 2005;76:2267-2275.
37. Wright HJ, Chapple IL, Matthews JB. TGF-beta isoforms and TGF-beta receptors in drug-induced and hereditary gingival overgrowth. J Oral Pathol Med 2001;30:281-289.
38. Cotrim P, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD. Cyclosporin A induces proliferation in human gingival fibroblasts via induction of transforming growth factor-beta1. J Periodontol 2003;74:1625-1633.
39. Buduneli N, Kütükçüler N, Aksu G, Atilla G. Evaluation of transforming growth factor-beta 1 level in crevicular fluid of cyclosporin A-treated patients. J Periodontol 2001;72:526-531.
40. Wright HJ, Chapple IL, Matthews JB. Levels of TGF beta1 in gingival crevicular fluid during a 21-day experimental model of gingivitis. Oral Dis 2003;9:88-94.
41. Park HH, Park IH, Cho JS, Lee YM, Lee HM. The effect of macrolides on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy 2010;24:348-353.
42. Rawlinson A, Dalati MH, Rahman S, Walsh TF, Fairclough AL. Interleukin-1 and IL-1 receptor antagonist in gingival crevicular fluid. J Clin Periodontol 2000;27:738-743.
43. Morton RS, Dongari-Bagtzoglou AI. Regulation of gingival fibroblast interleukin-6 secretion by cyclosporine A. J Periodontol 1999;70:1464-1471.
44. Atilla G, Kütükçüler N. Crevicular fluid interleukin-1beta, tumor necrosis factor-alpha, and interleukin-6 levels in renal transplant patients receiving cyclosporine A. J Periodontol 1998;69:784-790.
45. Pradeep AR, Prapulla DV, Sharma A, Sujatha PB. Gingival crevicular fluid and serum vascular endothelial growth factor: their relationship in periodontal health, disease and after treatment. Cytokine 2011;54:200-204.
46. Lucarini G, Zizzi A, Aspriello SD et al. Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study. J Clin Periodontol 2009;36:3-10.
47. Unlü F, Güneri PG, Hekimgil M, Yeşilbek B, Boyacioǧlu H. Expression of vascular endothelial growth factor in human periodontal tissues: comparison of healthy and diabetic patients. J Periodontol 2003;74:181-187.
48. Güneri P, Unlü F, Yeşilbek B et al. Vascular endothelial growth factor in gingival tissues and crevicular fluids of diabetic and healthy periodontal patients. J Periodontol 2004;75:91-97.
49. Alptekin NÖ, Ustün K, Yaprak E, Avunduk MC, Ataoǧlu T. Immunohistochemical analysis of CD45RO+ T cells and vascular endothelial growth factor expression in cyclosporin A-induced rat gingival tissue. J Periodontol 2012;83:248-255.
50. Cetinkaya BO, Acikgoz G, Ayas B, Aliyev E, Sakallioglu EE. Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats. J Periodontol 2006;77:54-60.
51. Koh JT, Kim OJ, Park YS et al. Decreased expressions of thrombospondin 2 in cyclosporin A-induced gingival overgrowth. J Periodontal Res 2004;39: 93-100.
52. Ho W, Eubank T, Leblebicioglu B, Marsh C, Walters J. Azithromycin decreases crevicular fluid volume and mediator content. J Dent Res 2010;89:831-835.